Laurus Labs Ltd (LAURUSLABS) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 86501.22 Cr. Figures below are as reported and are shown with their source and date.
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The company is headquartered in Hyderabad, Telangana and currently employs 5,753 full-time employees. The company went IPO on 2016-12-19. The firm offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The firm operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The firm operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The firm sell its APIs in 56 countries.
Source: finedge · as of 2026-09-29
Last close (₹): 2,002.5
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 6,812.9 | 888.79 | 16.46 |
| Mar 2025 | 5,553.96 | 358.32 | 6.64 |
| Mar 2024 | 5,040.83 | 160.55 | 2.98 |
| Mar 2023 | 6,040.55 | 790.11 | 14.67 |
| Mar 2022 | 4,935.57 | 827.52 | 15.4 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Source: nse · as of 2026-10-05
Figures computed 2026-10-23.